口服氨甲环酸辅助治疗印度黄褐斑患者的三盲随机安慰剂对照研究
该研究纳入130例面部黄褐斑患者,随机分为口服氨甲环酸250mg每日两次联合外用氟轻松基三联霜组与安慰剂联合外用三联霜组,治疗12周并随访至24周。结果显示联合组在mMASI改善率和持续改善率上均显著优于对照组,复发率更低。口服氨甲环酸作为三联霜的辅助治疗可更快、更持久地改善黄褐斑并减少复发。
要点
- 口服氨甲环酸250mg每日两次联合外用三联霜可显著提高黄褐斑mMASI改善率。
- 联合组12周时65.6%患者mMASI改善>75%,对照组仅27.1%。
- 24周时联合组复发率18.03%,显著低于对照组的64.4%。
核心结论
- 口服氨甲环酸作为氟轻松基三联霜的辅助治疗,对黄褐斑可提供更快、更持久的改善并预防复发。
研究设计与样本
- Group A口服氨甲环酸250mg和雷尼替丁150mg每日两次,外用含0.01%氟轻松、0.05%维A酸和2%氢醌的三联霜每日一次;Group B口服安慰剂片(乳酸钙和复合维生素)并外用三联霜,疗程12周。
- 共120例完成研究(A组61例,B组59例),采用mMASI评估第4、8、12周改善及第24周复发。
主要发现
- 第4周时A组13.1%患者mMASI改善>75%,B组为1.7%。
- 第12周时A组65.6%患者mMASI改善>75%,B组为27.1%。
- 第24周时A组65.6%维持改善,B组为11.9%,差异均有统计学意义。
- 第24周复发率A组18.03%,B组64.4%。
关键数值与推荐
- mMASI改善>75%定义为显著改善。
- 口服氨甲环酸250mg每日两次联合雷尼替丁150mg每日两次,外用三联霜每日一次,疗程12周。
临床怎么用
- 对黄褐斑患者可考虑在氟轻松基三联霜基础上加用口服氨甲环酸250mg每日两次作为辅助治疗,以加快改善并降低复发。
局限性
- 单中心研究,样本完成分析120例,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Melasma is a chronic recalcitrant pigmentary disorder whose treatment frustrates physician and patient alike. Tranexamic acid, a plasmin inhibitor, has demonstrated hypopigmenting properties. AIM: To compare safety and efficacy of combination of oral tranexamic acid (TXA) and topical fluocinolone-based combination cream (FbTC) with that of topical FbTC alone in melasma. METHOD: One hundred and eighty patients patients of facial melasma of either sex attending dermatology OPD were screened. Consenting 130 participants were randomized into two blinded groups with 65 patients in each group. Group A patients received oral tranexamic acid 250 mg and oral ranitidine 150 mg twice daily and applied a triple combination cream containing fluocinolone acetonide 0.01%, tretinoin 0.05% and hydroquinone 2% once daily, and Group B was asked to take placebo tablets (calcium lactate and multivitamin) and apply the cream only for 12 weeks. Response was evaluated using modified melasma area severity index (mMASI) and graded mMASI improvement at 4th, 8th and 12th weeks, and at 24th week for recurrence. Data were analysed using SPSS software. RESULTS: Results were analysed in 120 patients who completed the study with 61 and 59 patients in group A and B, respectively. Demographic profile was equally distributed in both the groups. In group A, 13.1% patients showed marked improvement (>75%) in mMASI as compared to group B (1.7%) at 4th week. By 12th week, 65.6% patients had marked improvement in group A in contrast to only 27.1% in group B. At 24th week, group A (65.6%) had sustained improvement as compared to group B (11.9%) despite stopping treatment; all of which were statistically significant. Recurrence observed was 18.03% in group A vs. 64.4% in group B at 24th week. CONCLUSION: Oral tranexamic acid is definitely a boon to the armamentarium of melasma management and should be used as an adjuvant to fluocinolone-based triple combination cream for a faster, sustained improvement and to prevent recurrence.
引用
- Minni K, Poojary S. Efficacy and safety of oral tranexamic acid as an adjuvant in Indian patients with melasma: a prospective, interventional, single-centre, triple-blind, randomized, placebo-control, parallel group study. J Eur Acad Dermatol Venereol. 2020. PMID: 32567734. doi:10.1111/jdv.16598
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。